BIOV.F Stock Overview An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Swedish Orphan Biovitrum AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Swedish Orphan Biovitrum Historical stock prices Current Share Price SEK 27.66 52 Week High SEK 32.25 52 Week Low SEK 22.87 Beta 0.24 1 Month Change -2.26% 3 Month Change -11.64% 1 Year Change 13.59% 3 Year Change 38.33% 5 Year Change 70.22% Change since IPO 178.97%
Recent News & Updates
Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors Dec 11
Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair Nov 05
Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study Oct 28 Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025 Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025
Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN Aug 08 See more updates
Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors Dec 11
Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair Nov 05
Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study Oct 28 Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025 Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025
Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN Aug 08
Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct Jul 19
Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024 Jul 17
Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024 Jul 16
Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout Jul 02
European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A Jun 20
Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member May 15
Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024 Apr 28 Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025
Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024 Feb 29
Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024 Feb 08
Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member Jan 05
Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024 Oct 31
Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G Oct 18
Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer Oct 05 Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A Sep 25
Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion. Sep 21 Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion. Sep 20
Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024
Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders. Jun 27
European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A May 19
Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion. May 11
Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board May 10
Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023 Feb 08
Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes Feb 03
ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine) Dec 21
Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia Nov 11
Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023 Nov 01 Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Sep 17
Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa Aug 30
Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022 Jul 20
Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress Jun 10
Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need Jun 08
FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi Jun 01
Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member May 12
Sanofi and Swedish Orphan Biovitrum AB Announce Positive Topline Results from the Pivotal XTEND-1 Phase 3 Study Mar 10
Gamifant (Emapalumab) Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH) Feb 26
Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 10, 2022 Feb 01
Kineret® (Anakinra) Receives Positive Opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Treatment of Patients with Covid-19 Pneumonia Dec 18 Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population Dec 15
Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (publ) (OM:SOBI) from Investor AB (publ) (OM:INVE A), AP Fonden 4 and others. Dec 05
Swedish Orphan Biovitrum AB (publ) Publishes Positive Phase 3 Anakinra Study Results in Patients with COVID-19 Pneumonia Sep 08
Nature Medicine Publishes Phase 3 Anakinra Study Results in Patients with Covid-19 Pneumonia Sep 04
Orphan Biovitrum Jumps After Bloomberg Report of Potential Takeover Aug 27
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH May 26
Swedish Orphan Biovitrum AB (publ) Announces Early Use of Anakinra Reduces Risk of Mortality for Patients with Covid-19 Pneumonia, Reduces ICU Admission and Increases Likelihood of Full Recovery May 21
Swedish Orphan Biovitrum AB (Publ) and Hellenic Institute for the Study Announce Positive Top Line Results from the Investigator-Sponsored Save-More Study May 05
Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Full Year 2021 May 04
The NEJM Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH Mar 19
Swedish Orphan Biovitrum AB (publ) Announces First Patient Dosed with Avatrombopag Mar 13
Swedish Orphan Biovitrum AB (publ) Announces Approval of Kineret® (anakinra) in Russia for the Treatment of CAPS Feb 18
Swedish Orphan Biovitrum AB (publ) Announces Doptelet (avatrombopag) Approved in the EU for Treatment of ITP Jan 22
Swedish Orphan Biovitrum AB (Publ) Appoints Duane Barnes as the New Head of Sobi in North America Dec 23 Swedish Orphan Biovitrum's Doptelet® (Avatrombopag) Receives Positive Opinion from CHMP for Treatment of ITP
Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals Inc. Reports Positive Top-Line Results At 48 Weeks from the Phase 3 Pegasus Study of Pegcetacoplan in PNH Dec 11
Sobi and Apellis Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan Nov 20
Swedish Orphan Biovitrum AB (publ) Announces CHMP Adopts Negative Opinion for Emapalumab in Europe for the Treatment of Primary HLH Nov 14
Sobi launch Doptelet® (avatrombopag) in Europe Nov 05
Swedish Orphan Biovitrum AB (Publ) Announces Favorable Paediatric Data Results in Alprolix ® Product Information Update Oct 30
Apellis, Enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications Outside the US Oct 29
Sobi™ Presents Results from the Sensitivity Analysis from the Pivotal Phase 2/3 Study Oct 18
Swedish Orphan Biovitrum AB (Publ) Announces Phase 3 Data of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia Oct 11
Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout Oct 02 Swedish Orphan Biovitrum AB (Publ) and Selecta Biosciences, Inc. Announce Topline Data of SEL-212 from the Phase 2 Compare Study
Swedish Orphan Biovitrum AB (Publ) Announces the Commencement of the Phase 3 Clinical programme of SEL-212 for Chronic Refractory Gout Sep 24
Swedish Orphan Biovitrum AB (publ) Announces Orfadin® (nitisinone) Receives Positive Opinion from CHMP for Treatment of AKU Sep 19 Shareholder Returns BIOV.F US Biotechs US Market 7D -3.4% -3.8% -2.7% 1Y 13.6% -2.6% 23.4%
See full shareholder returns
Return vs Industry: BIOV.F exceeded the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: BIOV.F underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is BIOV.F's price volatile compared to industry and market? BIOV.F volatility BIOV.F Average Weekly Movement n/a Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: BIOV.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BIOV.F's volatility change over the past year.
About the Company Founded Employees CEO Website 1939 1,814 Guido Oelkers www.sobi.com
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra.
Show more Swedish Orphan Biovitrum AB (publ) Fundamentals Summary How do Swedish Orphan Biovitrum's earnings and revenue compare to its market cap? BIOV.F fundamental statistics Market cap US$9.66b Earnings (TTM ) US$318.12m Revenue (TTM ) US$2.30b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BIOV.F income statement (TTM ) Revenue SEK 25.44b Cost of Revenue SEK 5.44b Gross Profit SEK 19.99b Other Expenses SEK 16.48b Earnings SEK 3.51b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
Earnings per share (EPS) 10.23 Gross Margin 78.60% Net Profit Margin 13.82% Debt/Equity Ratio 47.1%
How did BIOV.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 00:06 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Swedish Orphan Biovitrum AB (publ) is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alexander Lindström ABG Sundal Collier Rosie Turner Barclays Brian Balchin Barclays
Show 26 more analysts 
